EUVIMEDEUVIMED entdecken
Crossref

Synergistic Methylene Blue-Driven FAPI Uptake Mechanism Advancing the Detection of Myocardial Fibrosis in Hypertensive Heart Disease

Dimei Zhang, Guiting Li, Bingfeng Jiang, Yuxuan Li, Xingyang Zhao, Zhenxi Zhang, Na Chen, Xingmei Zhang, Mingfang Wang, Guoxia Zhang iD, Chuangyan Zhai iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Dimei Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China. Hauptthemen laut MEDLINE: Myocardium, Hypertension, Cardiomyopathies. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial fibrosis, a key pathological feature of hypertensive heart disease (HHD), remains diagnostically challenging due to limited clinical tools. In this study, a FAPI-targeted uptake mechanism previously reported by our group, originally developed for tumor imaging, is extended to the detection of myocardial fibrosis in HHD using [18F]F-NOTA-FAPI-MB. The diagnostic performance of this tracer is compared with those of [18F]F-FDG, [18F]F-FAPI-42, and [18F]F-NOTA-FAP2286, and its potential for fluorescence imaging is also evaluated. Myocardial fibrosis associated with HHD was induced in Sprague-Dawley rats using isoproterenol. Evaluation of cardiac structure and function was conducted through echocardiography. Following each administration of a radioactive tracer via tail vein injection, static PET/CT imaging was performed at 1 and 2 h after injection. Additionally, cardiac excision allowed for ex vivo fluorescence imaging using NOTA-FAPI-MB. All three FAP-targeting probes enabled the precise localization and quantification of fibrotic activity within affected myocardial regions. Among them, [18F]F-NOTA-FAPI-MB demonstrated the most pronounced increase in TBR from 1 to 2 h in the ISO group and exhibited the highest 2 h/1 h ratio. Blocking experiments revealed limited competitive inhibition of the [18F]F-NOTA-FAPI-MB uptake by unlabeled FAPI-42. Ex Vivo cardiac fluorescence imaging further confirmed the significant accumulation of NOTA-FAPI-MB. [18F]F-FAPI-42 exhibited an inferior retention ability at the target site compared to [18F]F-NOTA-FAPI-MB. In contrast, [18F]F-NOTA-FAP2286 showed a lower uptake and the weakest retention in fibrotic regions among the three tracers. However, [18F]F-FDG imaging showed no significant changes in myocardial metabolic activity in HHD, suggesting that [18F]F-FDG imaging is not effective in detecting cardiac abnormalities associated with HHD. The successful translation of the MB-driven uptake mechanism from tumors to HHD is evidenced by the enhanced myocardial accumulation of [18F]F-NOTA-FAPI-MB via MB synergy, confirming its mechanism-based targeting. Although further clinical validation is required, this radiopharmaceutical holds strong potential as a dual-modality imaging agent for HHD with a reduced radiation burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocardiumHypertensionCardiomyopathiesAnimalsRats, Sprague-DawleyRatsFibrosisMalePositron Emission Tomography Computed TomographyRadiopharmaceuticalsIsoproterenolFluorodeoxyglucose F18Optical Imaging

Stichwörter der Autor:innen

PET/CTdiagnosishypertensive heart diseasemyocardial fibrosisradiopharmaceuticals

Substanzen

RadiopharmaceuticalsIsoproterenolFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China.
  • Research and Development Center, Guangdong Huixuan Pharmaceutical Technology Co., Ltd., Guangzhou 510765, China.
  • Research and Development Center, Guangzhou HTA Pharmaceutical Co., Ltd., Guangzhou 510630, China.
  • The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
  • Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, P. R. China.
  • Department of Pathology, Guangdong Women and Children Hospital, Guangzhou 511400, China.

ORCID-Profile: Guoxia Zhang, Chuangyan Zhai

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, D., Li, G., Jiang, B., Li, Y., Zhao, X., Zhang, Z., Chen, N., Zhang, X., Wang, M., Zhang, G., & Zhai, C. (2025). Synergistic Methylene Blue-Driven FAPI Uptake Mechanism Advancing the Detection of Myocardial Fibrosis in Hypertensive Heart Disease. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00913

Vancouver

Zhang D, Li G, Jiang B, Li Y, Zhao X, Zhang Z, et al. Synergistic Methylene Blue-Driven FAPI Uptake Mechanism Advancing the Detection of Myocardial Fibrosis in Hypertensive Heart Disease. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00913

BibTeX
@article{Zhang2025,
  author = {Zhang, Dimei and Li, Guiting and Jiang, Bingfeng and Li, Yuxuan and Zhao, Xingyang and Zhang, Zhenxi and Chen, Na and Zhang, Xingmei and Wang, Mingfang and Zhang, Guoxia and Zhai, Chuangyan},
  title = {Synergistic Methylene Blue-Driven FAPI Uptake Mechanism Advancing the Detection of Myocardial Fibrosis in Hypertensive Heart Disease},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00913}
}
Kostenlos starten →